trending Market Intelligence /marketintelligence/en/news-insights/trending/H6D6kh9ACumMXgo-KJ5_zg2 content esgSubNav
In This List

Novartis drug prolongs time to patients' first sickle cell pain crisis in study

Blog

Baird Research is Now Exclusively Available in S&P Global’s Aftermarket Research Collection

Blog

Japan M&A By the Numbers: Q4 2023

Blog

Essential IR Insights Newsletter Fall - 2023

Case Study

A Corporation Clearly Pinpoints Activist Investor Activity


Novartis drug prolongs time to patients' first sickle cell pain crisis in study

Novartis AG drug crizanlizumab delayed the time to first sickle cell pain crisis in patients versus placebo in key subgroups of adult patients with sickle cell disease in a phase 2 trial.

Acute sickle cell pain crises are a common painful complication of the disease and the main reason that patients seek medical care in hospitals. They are also known as vaso-occlusive crises.

The data will help support discussions with regulatory agencies, with filing expected in the U.S. by the end of 2018.